

Canadian Study of Adherence Outcomes in HUMIRA® (Adalimumab) Patients: Three-Year Results from the COMPANION Study in Gastroenterology Patients

John K. Marshall¹, Brad Millson², Michael Sung², Tania Gaetano³, Martin Latour³, Marie-Claude Laliberté³

¹Department of Medicine, Division of Gastroenterology, Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton, Ontario, Canada; ²IMS Brogan, Kirkland, Quebec, Canada; ³AbbVie Corporation, St. Laurent, Quebec, Canada

Canadian Digestive Diseases Week 2017 Annual Scientific Conference, March 3-6, Banff, Alberta, Canada

BACKGROUND

- HUMIRA® (adalimumab) was the first fully humanized biologic developed in the TNF-inhibitor class and is indicated for use in autoimmune diseases including Crohn's disease (CD) and ulcerative colitis (UC)^{1,2}
- Patient Support Programs (PSP) were first conceived in order to provide assistance with medication prescription costs, but are now increasingly providing additional services
- Patients receiving HUMIRA® in Canada are eligible to enroll in the AbbVie Care™ PSP providing a proprietary suite of services with the goal of improving patients' experiences and outcomes
- In addition to other services such as reimbursement support, financial assistance, and nursing services, among others, the HUMIRA® PSP services also include care coach calls (CCCs) prior to starting HUMIRA® (initial CCC) as well as during therapy (ongoing CCC)
- A previous study demonstrated increased adherence and persistence to HUMIRA® over a short period of time (i.e. 1 year) in patients enrolled in PSP and receiving CCCs compared to patients who don't receive CCCs³; however, there is limited evidence in Canada that demonstrates the long term impact of PSPs on patients' adherence and persistence to HUMIRA®

AIMS

- To assess the impact of patient characteristics (e.g. sex, age, diagnosis) and HUMIRA® PSP services (e.g. ongoing CCCs) on persistence and adherence to HUMIRA® over a 3-year period in the all-indication cohort and in a separate cohort of patients with CD and UC

METHODS

DATABASE LINKAGE AND STUDY DESIGN

- A probabilistic matching algorithm⁴ was developed to link patients in the HUMIRA® PSP database to patient-level medication transaction (LRx) data
- A 3-month look-forward period was used in order to ensure patient activity
- A 26-month selection period (July 2010 to August 2012) was used in order to select and index patients on the date of their first HUMIRA® script
- A 37-month study period was used in order to assess patient persistence and adherence



- Persistence to HUMIRA® was calculated by evaluating patients' prescriptions for 36 months following the index date to the end of therapy based on >90 days without transaction data, censored for patients who remained on therapy through month 36. Because the CCC service was only available in the PSP after June 2013, only patients that had demonstrated persistence up to July 2013 were compared
- Adherence to HUMIRA® was measured by evaluating patients' medication possession ratio (MPR) during their persistent period on therapy

PATIENT ELIGIBILITY

Inclusion Criteria:

- Enrolled in HUMIRA® PSP after July 2010
- Linked across PSP and longitudinal pharmacy data
- First HUMIRA® Rx between July 2010-August 2012
- For persistence measurement: patients had to be persistent on therapy for the first 12 months of HUMIRA

Exclusion Criteria:

- Received HUMIRA® for less than 30 days
- Index date > 90 days prior to enrollment in PSP

Statistical Analysis

- Cox regression analysis to determine hazard ratios (HR) for the association between persistence and covariates including patient characteristics and PSP services
- Multivariate logistic regression analysis to determine odds ratios (OR) for the relationship between high adherence (i.e. MPR ≥ 80%) and covariates including patient characteristics and PSP services
- Adjustments for multiple potential confounders in all regression analyses were performed

RESULTS

Figure 1. Patient Selection Results




Table 1. Study patient characteristics

	Total PSP Patients % (n=38,840)	Final Study Cohort % (n=4,772)
Gender		
Male	45%	45%
Age		
≤ 17	3%	1%
18-29	15%	9%
30-39	19%	17%
40-49	21%	21%
50-59	23%	24%
60-69	14%	17%
≥ 70	6%	11%
Diagnosis		
Crohn's disease	39%	40%
Ulcerative colitis	4%	2%
Rheumatoid arthritis	19%	19%
Psoriasis	13%	15%
SpA*	23%	22%
Other or undetermined	2%	2%


* SpA consists of patients with Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA)

- The final study cohort provided a good representation of all patients enrolled in the PSP based on demographics and diagnosis (table 1)

FACTORS CORRELATED TO PERSISTENCE AND ADHERENCE


- In the all-indication cohort, male patients were significantly more persistent (HR=0.866, p=0.0004) than female patients
- Older age groups (40-49, 50-59, 60-69, 70+) were more likely to be persistent relative to the 30-39 year category (HR=0.782, p=0.0001; HR=0.751, p<0.0001; HR=0.731, p<0.0001; HR=0.640, p<0.0001)
- Relative to the 30-39 year category, older age groups (40-49, 50-59, 60-69, 70+) had significantly greater odds of adherence (OR=1.301, p=0.0214; OR=1.395, p=0.0032; OR=1.440, p=0.0033; OR=2.076, p<0.0001)

Figure 2. 36-month persistence by receipt of ongoing care coach calls (CCCs) among patients in the all-indication cohort




- In the all-indication cohort, patients receiving ongoing CCCs were 65% less likely to cease treatment compared to the patients who were not receiving ongoing CCCs (HR=0.351, p<0.0001) (figure 2)

Figure 3. 36-month persistence by receipt of ongoing care coach calls (CCCs) for IBD patients



- CD and UC patients receiving ongoing CCCs were 63% less likely to cease treatment compared to IBD patients not receiving ongoing CCCs (HR=0.368, p<0.0001) (figure 3)

Figure 4. Patient distribution of adherence by MPR and by receipt of ongoing care coach calls (CCCs)



- In the all-indication cohort, patients receiving ongoing CCCs had 124.8% greater likelihood of being highly adherent (>80% MPR) compared to those who did not receive the ongoing CCCs (OR=2.248, p<0.0001) (figure 4)
- CD and UC patients receiving ongoing CCCs have 140.6% greater likelihood of being highly adherent (>80% MPR) compared to those who did not receive ongoing CCCs (OR=2.406, p<0.0001) (figure 4)

CONCLUSIONS

- Among patients in all-indication cohort as well as patients with IBD diseases, after controlling for confounders, ongoing care coach calls had a statistically significant association with greater persistence and adherence to HUMIRA® over the first 36 months of treatment
- Male patients and older age groups (40-49, 50-59, 60-69, 70+) were significantly more persistent to HUMIRA®
- Older age groups (40-49, 50-59, 60-69, 70+) were also significantly more adherent to HUMIRA®
- These insights may help refine interventions aiming at improving treatment persistence and adherence

REFERENCES

- Blandizzi C, et al. *Int J Immunopath and Pharm.* 2014; 27(S1): 1-10
- Lapadula G, et al. *Int J Immunopath and Pharm.* 2014; 27(S1): 33-48
- Geraga S, et al. *Arthritis Rheumatol.* 2016; 68 (Supp 10)
- Blakely T & Salmond C, et al. *Int J Epidemiol.* 2002; 31:1246-1252

ACKNOWLEDGMENTS

Project management support for this study was provided by Jennifer Glass from IMS Brogan. Analytical support was provided by Krishna Donepudi from IMS Brogan. Statistical support was provided by Driss Oraichi from IMS Brogan. This support was funded by AbbVie.

DISCLOSURES

Dr. John K. Marshall has served as a speaker for AbbVie, Allergan, Ferring, Janssen, Procter & Gamble, Shire, and Takeda. He has also served as a consultant for AbbVie, Allergan, Astra-Zeneca, Boehringer-Ingelheim, Celgene, Celltrion, Ferring, Hospira, Janssen, Merck, Pfizer, Procter & Gamble, Shire, and Takeda. Brad Millson and Michael Sung are employees of IMS Brogan and have collaborated to this study as a consultants paid by AbbVie. Tania Gaetano, Martin Latour and Marie-Claude Laliberté are employees of AbbVie and own AbbVie shares.